STOCKHOLM,
Sept. 27, 2018 /PRNewswire/
-- IRRAS AB (NASDAQ Stockholm: IRRAS) announced today that it
has added key talent to its commercial organization to drive sales
of the company's lead product,
IRRAflow®, in the United States. Steve Crowell, John
Gessert, Anthony Maestas, and
Bryan Whalen have joined IRRAS as
Territory Managers. In addition, John
Unser has joined IRRAS as a Senior Product Manager to lead
the marketing efforts for IRRAflow. These
individuals have over 60 years of relevant commercial medical
device experience and have shown significant success in bringing
innovative technologies to market and building them toward standard
of care.
After the addition of these first four Territory Managers,
IRRAS plans to continue the growth of its US salesforce in coming
months to meet growing interest for IRRAflow
and establish national clinical coverage.
"The United States is the
largest medical device market globally, and the recent FDA
clearance of IRRAflow offers a great
opportunity to enter this critically important market. The hiring
of these experienced, successful sales professionals will be a
great asset for our company as we finalize our plans to launch in
the US," said Will Martin, Chief
Commercial Officer of IRRAS.
"We are very excited about the possibilities for
IRRAflow in the US, and our ability to hire key
sales professionals is of paramount importance to our ability to
capture market share," said Kleanthis G.
Xanthopoulos, Ph.D., President and CEO of IRRAS.
For more information, please contact:
Sweden
Fredrik Alpsten
CFO and Deputy CEO
+46-706-67-31-06
fredrik.alpsten@irras.com
USA
Kleanthis G.
Xanthopoulos, Ph.D.
President & CEO
info@irras.com
About IRRAS
IRRAS AB (NASDAQ Stockholm: IRRAS) is a publicly-traded,
commercial-stage medical technology company focused on developing
and commercializing innovative solutions for brain surgery. The
Company's initial product, IRRAflow®, addresses
the complications associated with the current methods of managing
intracranial fluid by using a dual lumen catheter that combines
active irrigation with ongoing fluid drainage.
IRRAflow received FDA clearance in July 2018.
Regularly during treatment, the
IRRAflow catheter is automatically flushed to
prevent common catheter occlusions from forming. Because
IRRAflow is a completely closed system, it is
designed to reduce the documented
infection risk of these procedures. Additionally,
IRRAflow incorporates ICP monitoring and uses a
proprietary software to regulate treatment based on desired
pressure levels.
With its unique product portfolio, protected by property
patents and patent applications, IRRAS is well positioned to
establish a leadership position in the medical device market. IRRAS
maintains its headquarters in Stockholm,
Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier.
Wildeco is certified adviser of the Company.
The information was released for public disclosure,
through the agency of the contact person above, on September 27, 2018 at 8.00
a.m. (CET).
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/irras/r/irras-strengthens-us-commercial-organization-with-hiring-of-multiple-key-talents,c2629088
The following files are available for download:
http://mb.cision.com/Main/16550/2629088/916673.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/irras-strengthens-us-commercial-organization-with-hiring-of-multiple-key-talents-300720045.html
SOURCE IRRAS